Journal
FRONTIERS IN AGING NEUROSCIENCE
Volume 14, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fnagi.2022.1019412
Keywords
Alzheimer's disease; small molecule; A beta; tau protein; therapeutic drugs monitoring
Categories
Funding
- Taishan Scholars Project of Shandong Province
- [tsqn202103108]
Ask authors/readers for more resources
This review summarizes small-molecule drugs developed based on the pathogenesis of Alzheimer's disease (AD) and provides a deeper understanding of AD. It aims to assist scientists in finding new and better treatments to gradually conquer the problems associated with AD in the future.
Alzheimer's disease (AD) is an irreversible, progressive neurodegenerative brain disorder with no effective therapeutic drugs currently. The complicated pathophysiology of AD is not well understood, although beta-amyloid (A beta) cascade and hyperphosphorylated tau protein were regarded as the two main causes of AD. Other mechanisms, such as oxidative stress, deficiency of central cholinergic neurotransmitters, mitochondrial dysfunction, and inflammation, were also proposed and studied as targets in AD. This review aims to summarize the small-molecule drugs that were developed based on the pathogenesis and gives a deeper understanding of the AD. We hope that it could help scientists find new and better treatments to gradually conquer the problems related to AD in future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available